Fatty acylation of cysteine residues provides spatial and temporal control of protein function in cells and regulates important biological pathways in eukaryotes. Although recent methods have improved the detection and proteomic analysis of cysteine fatty (S-fatty) acylated proteins, understanding how specific sites and quantitative levels of this posttranslational modification modulate cellular pathways are still challenging. To analyze the endogenous levels of protein S-fatty acylation in cells, we developed a mass-tag labeling method based on hydroxylamine-sensitivity of thioesters and selective maleimide-modification of cysteines, termed acyl-PEG exchange (APE). We demonstrate that APE enables sensitive detection of protein S-acylation levels and is broadly applicable to different classes of S-palmitoylated membrane proteins. Using APE, we show that endogenous interferoninduced transmembrane protein 3 is S-fatty acylated on three cysteine residues and site-specific modification of highly conserved cysteines are crucial for the antiviral activity of this IFN-stimulated immune effector. APE therefore provides a general and sensitive method for analyzing the endogenous levels of protein S-fatty acylation and should facilitate quantitative studies of this regulated and dynamic lipid modification in biological systems.
Fatty acylation of cysteine residues provides spatial and temporal control of protein function in cells and regulates important biological pathways in eukaryotes. Although recent methods have improved the detection and proteomic analysis of cysteine fatty (S-fatty) acylated proteins, understanding how specific sites and quantitative levels of this posttranslational modification modulate cellular pathways are still challenging. To analyze the endogenous levels of protein S-fatty acylation in cells, we developed a mass-tag labeling method based on hydroxylamine-sensitivity of thioesters and selective maleimide-modification of cysteines, termed acyl-PEG exchange (APE). We demonstrate that APE enables sensitive detection of protein S-acylation levels and is broadly applicable to different classes of S-palmitoylated membrane proteins. Using APE, we show that endogenous interferoninduced transmembrane protein 3 is S-fatty acylated on three cysteine residues and site-specific modification of highly conserved cysteines are crucial for the antiviral activity of this IFN-stimulated immune effector. APE therefore provides a general and sensitive method for analyzing the endogenous levels of protein S-fatty acylation and should facilitate quantitative studies of this regulated and dynamic lipid modification in biological systems.
fatty-acylation | palmitoylation | PEGylation | influenza virus | IFITM3 P rotein S-fatty acylation describes the covalent attachment of long-chain fatty acids to cysteine (Cys) residues through a thioester bond, which alters the hydrophobicity of diverse proteins and regulates their stability, trafficking, and activity in eukaryotic cells (Fig. 1A) (1, 2) . Cys residues are predominately acylated with palmitic acid (S-palmitoylation), but can also be modified with longer chain and unsaturated fatty acids, thus more generally described as S-fatty acylation (1, 3, 4) . The fatty-acylation of Cys residues is regulated by the DHHC-family of protein acyltransferases (5, 6) and different classes of thioesterases (7, 8) that are associated with a variety of important physiological pathways and diseases (1) . Determining the precise levels of protein S-fatty acylation is therefore crucial for understanding how this dynamic lipid modification is regulated and quantitatively controls specific cellular pathways.
Recent methods to detect and enrich S-fatty acylated proteins have facilitated the characterization of key regulatory mechanisms and discovery of new S-fatty acylated proteins (1, 2) . For example, alkyne-modified fatty acid chemical reporters have enabled the fluorescent detection and enrichment of metabolically labeled proteins using bioorthogonal ligation methods (Fig.  S1A) (9, 10) . Alternatively, exploitation of thioester sensitivity to hydroxylamine (NH 2 OH) has enabled selective capture and analysis of S-acylated proteins by acyl-biotin exchange (ABE) (Fig. S1B) (11, 12) or acyl-resin capture (acyl-RAC) (Fig. S1C ) (13) . However, all of these methods do not readily reveal the fraction of unmodified versus S-fatty acylated proteins or the number of sites of S-acylation, which are both crucial for understanding how quantitative differences in S-fatty acylation control protein function and associated cellular phenotypes.
To evaluate endogenous levels of S-fatty acylation, we developed a mass-tag labeling method termed acyl-PEG exchange (APE) that exploits the NH 2 OH-sensitivity of thioesters and selective reactivity of Cys residues for site-specific alkylation with maleimide-functionalized polyethylene glycol reagents (Fig. 1B) . APE induces a mobility-shift on S-acylated proteins that can be readily monitored by Western blot of target proteins and circumvents the need for metabolic labeling or affinity enrichment of proteins. We demonstrate that APE can reveal endogenous levels, stoichiometry and specific sites of S-acylation on diverse S-palmitoylated proteins. Using APE, we characterized the endogenous levels of interferon-induced transmembrane protein 3 (IFITM3) S-fatty acylation and show that site-specific modifications of highly conserved Cys residues are crucial for the antiviral activity of this key IFN-induced immune effector. APE provides a sensitive and readily accessible method for evaluating endogenous S-fatty acylation levels and should facilitate the quantitative analysis of this dynamic lipid modification in diverse cell types and tissues.
Results

APE Enables Direct Visualization of S-Acylated Protein Isoforms.
To establish the utility of APE, we first analyzed HRas, a wellcharacterized S-palmitoylated protein. HRas contains one farnesylation site at Cys-186 and two S-palmitoylation sites at Cys-181 and 184, which regulate the trafficking and activity of this small GTPase at the plasma membrane and internal membrane compartments (14) . To explore mass-shift detection by APE, HEK293T cells were transfected with N-terminally HA-tagged HRas (HA-HRas) and lysed with SDS-containing buffer. Lysates were reacted with Tris(2-carboxyethyl)phosphine (TCEP) and N-ethylmaleimide (NEM) to reduce and block free Cys residues. Proteins were then treated with NH 2 OH to cleave thioesters, alkylated with methoxy-PEG-maleimide (mPEG-Mal), and analyzed
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Cysteine fatty acylation (S-fatty acylation) regulates the stability, trafficking, and activity of proteins in eukaryotes. Current methods to study S-fatty acylation rely on the metabolic incorporation of fatty acid analogs or selective chemical labeling and affinity purification, which limits the detection of endogenous S-fatty acylated protein isoforms and levels. Here we demonstrate that the biochemical exchange of acyl groups on cysteines with defined mass-tags enables the direct visualization of endogenous S-fatty acylated protein levels. The application of this mass-tag labeling method revealed that site-specific S-fatty acylation of interferon-induced transmembrane protein 3 controls the antiviral activity of this IFN-induced effector.
by Western blot (Fig. 2A) . Reaction of cell lysates with 5 kDa mPEG-Mal alone revealed three slower migrating HRas species, consistent with three unmodified Cys residues at positions 51, 80, and 118 on HRas that were blocked by pretreatment with NEM (lanes 1-3, Fig. 2A ). Cleavage of thioesters with NH 2 OH followed by mPEG-Mal alkylation resulted in unmodified polypeptide at 25 kDa (apo) and two slower migrating polypeptides, which corresponded to mono-PEGylated (*) and di-PEGylated (**) proteins (lane 4, Fig. 2A ). Reaction of cell lysates with 10 kDa mPEG-Mal induced a mass shift approximately twice that observed for the 5 kDa reagent, consistent with site-specific PEGylation (lane 5, Fig. 2A ). The NH 2 OH-dependent PEGylation-induced mass shift correlates with the two predicted sites of S-palmitoylation on HRas (14) . In parallel, we also analyzed endogenous calnexin (CANX), a type I integral membrane protein with two S-palmitoylation sites (15, 16) , which yielded mono-and di-PEGylated polypeptides, suggesting CANX is fully S-acylated under these conditions ( Fig. 2A) . To optimize APE detection of S-acylated proteins, we tested varying concentrations of NH 2 OH and mPEG-Mal for selective thioester cleavage and Cys alkylation of proteins, respectively. We determined that 0.75 M NH 2 OH treatment for 1 h and 1 mM mPEG-Mal labeling for 2 h was optimal for APE detection of transfected HA-HRas and endogenous CANX, which provides a useful protein loading control for APE ( Fig. S2 A and B) . Increasing concentrations of mPEG-Mal can result in nonspecific alkylation, as seen for CANX in samples not treated with NH 2 OH (Fig. S2C ). Rab7, a prenylated GTPase that is not S-palmitoylated (17) , was also analyzed and did not exhibit NH 2 OH-dependent PEGylation (Fig. S2B) , despite the presence of multiple Cys residues, confirming the specificity of the APE protocol for S-acylated proteins. To further characterize our protocol for APE, we evaluated the effect of Triton X-100 and EDTA in the lysis and reaction buffers. Although additional Triton X-100 was not necessary to further solubilize proteins in SDScontaining lysis buffer, EDTA was required for complete NH 2 OHdependent PEGylation of CANX, HRas, and IFITM3 ( Fig. S2 D and E). The addition of EDTA was particularly crucial during the NH 2 OH-treatment step of cell lysates, which likely chelates metals involved in oxidation of the newly liberated Cys residues that would interfere with subsequent PEGylation (Fig. S2 D and E) . Using this optimized APE protocol, a pan-Ras antibody readily detected the endogenous levels of mono-and di-S-fatty acylated Ras in HeLa cells ( Fig. 2B) , showing that the APE can reveal S-fatty acylation levels of other endogenously expressed proteins in addition to abundant proteins such as CANX.
We next compared our APE protocol with other protein S-acylation detection methods. In comparison with ABE (11, 12) or acyl-RAC (13) (Fig. S1 B and C), APE enables the direct visualization of the different S-acylated isoforms of endogenously expressed CANX and Ras. APE also circumvents the need for affinity enrichment of proteins required for ABE and acyl-RAC, which can yield incomplete recovery of membrane-associated proteins and confound estimates of S-acylated and unmodified protein levels (Fig. S3A) . With respect to the PEG-switch assay (PSA) (18) , the reported conditions showed incomplete NH 2 OHdependent PEGylation of CANX, Ras, and IFITM3 (lanes 2 and 8, Fig. S3B ). In the PSA protocol, 2 mM mPEG-Mal was added together with 200 mM NH 2 OH, which could react with the maleimide group and affect the efficiency of PEGylation. We therefore separated the NH 2 OH treatment and mPEG-Mal labeling steps by removing excess NH 2 OH with chloroform-methanol precipitation. Separating the NH 2 OH-mediated deacylation and maleimide alkylation reactions restored the PEGylation efficiency to levels similar to our APE conditions (lane 6, Fig. S3B ). Coincubation of NH 2 OH and mPEG-Mal in our APE protocol also significantly reduced the efficiency of PEGylation (lane 4, Fig. S3B ), confirming the need to separate these steps for optimal mass shift analysis. To further determine the specificity and utility of our APE protocol, we analyzed several different classes of S-palmitoyated proteins in parallel with CANX, which provides an important S-fatty acylated protein loading control that typically yields ∼1:1 ratio of mono-and di-S-acylated polypeptides with our optimized APE conditions. In addition to dually lipidated cell signaling factors such as HRas, APE can readily reveal the S-fatty acylation isoforms and levels of other small GTPases (IRGM1) (19) , multiple-pass membrane proteins (CD9) (20) , as well as IFITM3 (21, 22) (Fig. 2C) . The analysis of reported S-palmitoylation-deficient Cys mutants for these proteins confirms their sites of modification and shows the levels of S-fatty acylated isoforms when expressed in HEK293T cells. These results suggest our optimized NH 2 OH-mediated acylPEGylation exchange protocol, which separates Cys deacylation and PEGylation steps, provides a robust and general method to evaluate protein S-acylation levels.
APE shows S-acylated protein isoforms and their relative levels but does not reveal whether specific proteins are directly fatty acidmodified or the dynamics of modifications at specific sites. Indeed, other S-acylated proteins in mammalian cells (e.g., enzymes, involved in ubiquitin and ubiquitin-like protein modification) (23), also contain thioester intermediates that could be subject to NH 2 OH-mediated PEGylation. To characterize protein S-acylation levels relative to fatty acid incorporation, we directly compared HRas S-fatty acylation by APE (Fig. 1B) and metabolic labeling (Fig. S1A ). HEK293T cells were transfected with HA-HRas constructs, pulse-labeled with an alkyne-palmitic acid chemical reporter (alk-16), lysed, and analyzed by APE or subjected to bioorthogonal reaction with azide-rhodamine and in-gel fluorescence detection (Fig. 3) . APE analysis of HA-HRas showed three α-HA reactive polypeptides corresponding to ∼0.35 unmodified (apo), 0.51 monoPEGylated (*) and 0.14 di-PEGylated (**) species (Fig. 3A) . The single Cys mutants (C181S, C184S) revealed ∼0.20 unmodified and 0.80 mono-PEGylated species, and as expected, the double Cys mutant (C181S, C184S) revealed only unmodified HA-HRas at 25 kDa (Fig. 3A) . These results show that mutation of individual S-fatty acylation sites still afforded significant levels, ∼80%, of mono-S-acylated HRas (Fig. 3A) . In contrast, metabolic labeling with alk-16 and in-gel fluorescence detection showed at least 50% decrease in labeling of single Cys mutants of HA-HRas (Fig. 3B) . These results suggest that mono-S-fatty acylated HA-HRas is relatively stable, whereas dual S-fatty acylation is more dynamically regulated, which is consistent with previous studies of HRas fatty acylation, localization, and activity (14) . This direct comparison highlights the utility of monitoring protein S-fatty acylation with both APE and metabolic labeling, which reveals the relative levels of unmodified and S-fatty acylated protein isoforms as well as site-specific differences in dynamic S-fatty acylation.
IFITM3 Antiviral Activity Is Controlled by Specific S-Fatty Acylation
Sites and Levels. We next focused on sites and levels of IFITM3 S-fatty acylation, which was discovered by our laboratory from alk-16 metabolic labeling and proteomic studies (21, 22) . Our initial studies demonstrated that the mutation of all three Cys residues (71, 72, and 105) to alanine (Ala) in murine IFITM3 abrogated S-fatty acylation and decreased antiviral activity (21, 22) . However, the endogenous levels of IFITM3 S-fatty acylation and specific sites of modification have not been characterized directly. APE analysis of endogenously expressed IFITM3 in IFN/LPS-stimulated murine NIH 3T3 fibroblasts and Raw264.7 macrophages revealed three slower migrating PEGylated polypeptides that correspond to the mono, di-, and tri-Sfatty acylated isoforms of mIFITM3 (Fig. 4A and Fig. S4A ). Similar APE results were also observed for human IFITM3 in IFN-stimulated A549 lung epithelial cells (Fig. S5A) , demonstrating that the majority, if not all, of endogenously expressed IFITM3 in IFNstimulated cells is S-fatty acylated on at least one Cys residue. To evaluate the contribution of individual Cys residues on IFITM3 S-fatty acylation, we generated single and double Cys mutants and analyzed their levels of S-fatty acylation by APE and metabolic labeling. APE analysis of the wild-type and the individual Cys to Ala HA-mIFITM3 mutants transfected into unstimulated murine NIH 3T3 fibroblasts showed that mutation of Cys71 and 105 to Ala eliminated the tri-S-acylated fraction and decreased the levels of the mono-and di-S-acylated mIFITM3 (Fig. 4B and Fig. S4B ). In contrast, the C72A mutant or multiple Cys mutants abrogated the tri-and di-S-acylated IFITM3 and even lost the mono-S-acylated fraction for the C72,105A mutant (Fig. 4B) . Similar APE results were also observed with human IFITM3 constructs expressed in HEK293T cells (Fig. S5B) . Metabolic labeling of these HAmIFITM3 Cys mutants with alk-16 and in-gel fluorescence detection also revealed C72 is the major site of S-fatty acylation in NIH 3T3 fibroblasts (Fig. 4C ) and HEK293T cells (Fig. S4C ). C72 is highly conserved among IFITM isoforms (24, 25) and is also a key site of S-fatty acylation for human IFITM1, -2, and -3 (Fig.  S5C) . The comparison of APE and alk-16 labeling suggests that, although the C72A IFITM3 mutant is still significantly mono-Sfatty acylated (Fig. 4B and Figs. S4B and S5B ), the majority of fatty acid metabolic labeling is abrogated (Fig. 4C and Figs. S4C  and S5C ). These results demonstrate that, similar to HRas (Fig.  3) , mono-S-fatty acylation of IFITM3 is relatively stable but dual S-fatty acylation is more dynamically regulated.
To determine the functional significance of site-specific IFITM3 S-fatty acylation, we evaluated the cellular localization and antiviral activity of these IFITM3 Cys mutants. Consistent with previous overexpression and immunofluorescence studies (21, 26, 27) , the majority of wild-type HA-mIFITM3 constructs colocalized with lysosomes marked by LAMP1-GFP in NIH 3T3 fibroblasts (Fig. S6A) . A minor fraction of HA-mIFITM3 also colocalized with GFP-Rab5 and Rab7-labeled endocytic vesicles (Fig. S6 C  and B) . Despite their differences in protein S-fatty acylation levels (Fig. 4) , mIFITM3 Cys mutants showed similar cellular distribution in NIH 3T3 fibroblasts by quantitative immunofluorescence analysis (Fig. S6 A-D) . Similar cellular distribution was also observed for the wild-type and HA-hIFITM3 Cys mutants in HEK293T cells (Fig. S7) . Nonetheless, these IFITM3 Cys mutants exhibited site-specific effects on antiviral activity against influenza virus infection (Fig. 4D and Fig. S8 ). To evaluate the site-specific effects of S-fatty acylation on IFITM3 antiviral activity, unstimulated NIH 3T3 cells were transfected with the HA-mIFITM3 constructs, then infected with influenza virus (PR8) and the percentage of infected cells was quantified by anti-influenza nuclear protein (NP) staining using flow cytometry, as previously described (21, 22) . Our results show that the C71A mutation does not significantly impair HA-mIFITM3 antiviral activity compared with wild-type, whereas C72A and C105A mutants show ∼50% decrease in antiviral activity (Fig. 4D and Fig. S8A ). The double Cys mutants of mIFITM3 also exhibited diminished antiviral activity, with the C71,72A mutant showing loss of antiviral activity comparable to the S-fatty acylation-deficient C71,72,105A mutant ( Fig. 4D and Fig. S8A ). Similar antiviral activity for the murine and human IFITM3 Cys mutants were observed in HEK293T cells (Fig.  S8 B and C) . These results demonstrate that, whereas site-specific differences in S-fatty acylation do not significantly affect IFITM3 cellular distribution upon overexpression, the lower levels of S-fatty acylation at specific Cys residues decrease IFITM3 antiviral activity.
Discussion and Conclusion
The functional roles of protein S-fatty acylation in eukaryotes are expanding from proteomic studies and characterization of regulatory enzymes (1, 2) . To understand the biological significance of protein S-fatty acylation in diverse biological pathways and disease, robust methods are needed for quantifying S-fatty acylated protein isoforms and levels. Inspired by mass shift-based assays for evaluating membrane topology of proteins (28), oxidation of Cys residues (29) , and protein glycosylation (30, 31) , we demonstrate that the NH 2 OH-mediated APE provides a sensitive and readily accessible method for determining the S-acylation levels of specific proteins that is not possible by previously reported methods using metabolic labeling or affinity enrichment (Fig. 1B) . APE enables the direct visualization of overexpressed and endogenous levels of S-acylated protein isoforms by Western blot analysis and is broadly applicable to different classes of S-fatty acylated proteins (Fig. 2) . The combination of APE and metabolic labeling provides complementary methods to visualize different isoforms as well as the levels and dynamics of S-fatty acylation (Fig. 3) .
Using APE we demonstrate that endogenous IFITM3 is mostly S-fatty acylated in IFN-stimulated cells and that S-fatty acylation of specific Cys residues and levels are crucial for IFITM3 antiviral activity against influenza virus. The bioinformatic analysis of IFITM isoforms in diverse vertebrates shows that these three S-fatty acylated Cys residues (C71, -72, and -105 in mIFITM3) are highly conserved within this family of membrane proteins (Fig. S9) (24, 25) . Notably, our APE analysis and fatty acid metabolic labeling show, to our knowledge for the first time, that the majority of endogenous IFITM3 is S-fatty acylated in IFN-stimulated cells and Cys72 is the most prominent S-fatty acylation site (Fig. 4) . Although previous studies have suggested that mutation of these conserved Cys residues may partially affect the localization or trafficking of IFITMs in mammalian cells (21, 22, 27, 32) , our quantitative immunofluorescence analysis suggest that site-specific S-fatty acylation may regulate more subtle functions of IFITM3 beyond lysosomal targeting (Figs. S7 and S8), such as protein-protein interactions (33, 34) or membrane tethering, but which awaits more detailed biochemical or biophysical studies. Nonetheless, these differences in site-specific S-fatty acylation have significant effects on IFITM3 antiviral activity. In murine and human IFITM3, even though Cys71 is highly conserved, this residue is dispensable for dual S-fatty acylation and antiviral activity (Fig. 4) . In contrast, Cys72 in IFITM3 is the most prominent site of S-fatty acylation and results in the loss of antiviral activity when mutated to Ala (Fig. 4 and Figs. S5 and S6) . The S-fatty acylation and antiviral activity of Cys105 may depend on the IFITM isoform, expression levels and cell-type, as the mutation of this Cys residue decreases murine IFITM3 antiviral activity but is not required for human IFITM3 activity (Fig. 4 and Figs. S5 and S6) . Our results are consistent with previous IFITM mutagenesis and antiviral activity studies (21, 22, 27, 32, 35) , but demonstrates that antiviral activity is directly correlated to S-fatty acylation levels and that dually S-fatty acylated IFITM3 at Cys72 and Cys105 is likely the most active isoform in mammalian cells (Fig. S9) . In summary, we demonstrate that NH 2 OH-mediated APE provides a sensitive and readily accessible method to measure S-fatty acylation levels on diverse proteins in different cell types that should greatly facilitate the analysis of protein S-fatty acylation in physiology and disease.
Materials and Methods
For APE, cell samples were lysed with 4% (wt/vol) SDS (Fischer) in TEA buffer [pH 7.3, 50 mM triethanolamine (TEA), 150 mM NaCl] containing 1× protease inhibitor mixture (Roche), 5 mM PMSF (Sigma), 5 mM EDTA (Fischer), and 1,500 units/mL benzonase (EMD). The protein concentration of the cell lysate was then measured using a BCA assay (Thermo) and adjusted to 2 mg/mL with lysis buffer. Typically, 200 μg of total protein in 92.5 μL of lysis buffer was treated with 5 μL of 200 mM neutralized TCEP (Thermo) for final concentration of 10 mM TCEP for 30 min with nutation. NEM (Sigma), 2.5 μL from freshly made 1 M stock in ethanol, was added for a final concentration of 25 mM and incubated for 2 h at room temperature. Reductive alkylation of the proteins was then terminated by methanol-chloroform-H 2 O precipitation (4:1.5:3) with sequential addition of methanol (400 μL), chloroform (150 μL), and distilled H 2 O (300 μL) (all prechilled on ice). The reactions were then mixed by inversion and centrifuged (Centrifuge 5417R, Eppendorf) at 20,000 × g for 5 min at 4°C. To pellet the precipitated proteins, the aqueous layer was removed, 1 mL of prechilled MeOH was added, the Eppendorf tube inverted several times and centrifuged at 20,000 × g for 3 min at 4°C. The supernatant was then decanted, and the protein pellet washed once more with 800 μL of prechilled MeOH, centrifuged again, and dried using a speed-vacuum (Centrivap Concentrator, Labconco) To ensure complete removal of NEM from the protein pellets, the samples were resuspended with 100 μL of TEA buffer containing 4% SDS, warmed to 37°C for 10 min, briefly (∼5 s) sonicated (Ultrasonic Cleaner, VWR), and subjected to two additional rounds of methanol-chloroform-H 2 O precipitations, as described above.
For hydroxylamine (NH 2 OH) cleavage and mPEG-maleimide alkylation, the protein pellet was resuspended in 30 μL TEA buffer containing 4% SDS, 4 mM EDTA and treated with 90 μL of 1 M neutralized NH 2 OH (J. T. Baker) dissolved in TEA buffer pH 7.3, containing 0.2% Triton X-100 (Fisher) to obtain a final concentration of 0.75 M NH 2 OH. Protease inhibitor mixture or PMSF should be omitted, as these reagents can interfere with the NH 2 OH reactivity. Control samples not treated with NH 2 OH were diluted in 90 μL TEA buffer with 0.2% Triton X-100. Samples were incubated at room temperature for 1 h with nutation. The samples were then subjected to methanol-chloroform-H 2 O precipitation, as described above, and resuspended in 30 μL TEA buffer containing 4% SDS, 4 mM EDTA, warmed to 37°C for 10 min, and briefly (∼5 s) sonicated and treated with 90 μL TEA buffer with 0.2% Triton X-100 and 1.33 mM mPEG-Mal (5 or 10 kDa; Sigma) for a final concentration of 1 mM mPEG-Mal. Samples were incubated for 2 h at room temperature with nutation before a final methanol-chloroform-H 2 O precipitation. Dried protein pellets were resuspended in 50 μL 1× Laemmli buffer (Bio-Rad) and then heated for 5 min at 95°C. Typically, 15 μL of the sample was loaded in 4-20% Criterion-TGX Stain Free polyacrylamide gels (Bio-Rad), separated by SDS/PAGE, and analyzed by Western blot. For Western blots, primary antibodies used were anticalnexin (1:2,000 ab22595; Abcam), Fig. 4 . Murine IFITM3 S-fatty acylation levels, sites of modification and antiviral activity. (A) NIH 3T3 or Raw264.7 macrophages were activated with 500 ng/mL LPS, 100 U/mL IFN-γ for 16 h, subjected to APE, and analyzed by Western blot. (B) NIH 3T3 cells transfected with WT HA-mIFITM3, or Cys to Ala mutant constructs were subjected to APE and analyzed by Western blot. The number of PEGylation events are indicated by asterisks (*). Analysis of whole-cell lysate (WCL) indicates levels of protein expression without APE. (C) NIH 3T3 cells transfected with HA-mIFITM3 constructs were metabolically labeled for 2 h with 50 μM alk-16. Cell lysates prepared with 1% Brij 97 were subjected to immunoprecipitation with anti-HA agarose-beads, reacted with az-rho by CuAAC, separated by SDS/PAGE, and visualized by fluorescence gel scanning. Comparable protein loading was confirmed by anti-HA Western blotting. (D) NIH 3T3 cells were transfected with HAmIFITM3 constructs, followed by infection with PR8 influenza virus at a multiplicity of infection of 5 for 18 h. Cells were fixed, permeabilized with 0.1% Triton X-100, and stained with anti-influenza NP antibody and analyzed by flow cytometry. Graph shows anti-influenza NP + cells for each condition; average of triplicate.
Error bar represents SEM, n = 3.
